Abstract:Bupropion had been in use since the late 1980s as an unconventional treatment for depression. Unlike other antidepressants, bupropion has no serotonergic activity and inhibits the reuptake of norepinephrine and dopamine. The drug has been used to treat depression, Attention Deficit Hyperactivity Disorder (ADHD), and smoking cessation. This investigation reviews the pharmacokinetic and pharmacodynamic effects of bupropion and its mechanisms of action and interactions with other drugs. We evaluated the efficacy of major on and off-label uses of bupropion, focusing on the indications, benefits, and adverse effects. Our review demonstrates that bupropion is superior to placebo and non-inferior to SSRIs such as escitalopram in treating major depressive disorder. More research is needed to determine positive patient-centered outcomes such as increases in quality of life. In the case of ADHD, the evidence for efficacy is mixed with poorly conducted randomized clinical trials, small sample sizes, and a lack of long-term assessments. The same is true in the case of bipolar disorder in which there is still limited and controversial data available on bupropion's safety and efficacy. In the case of smoking cessation, bupropion is found to be an effective anti-smoking drug with synergistic benefits when used as a combination therapy. We conclude that bupropion has the potential to provide benefit for a subset of patients who do not tolerate other typical antidepressants or anti-smoking therapies or for those whose treatment goals align with bupropion's unique side effect profile, such as smokers who wish to quit and lose weight. Additional research is needed to determine the drug's full clinical potential, particularly in the areas of adolescent depression and combination therapy with varenicline or dextromethorphan. Clinicians should use this review to understand the varied uses of the drug and identify the situations and patient populations in which bupropion can lend its greatest benefit.

Bupropion-sustained release in treatment of depression (72 patients) : a randomized, double-blind, doubledummy, multi-center clinical trial

Treatment with Bupropion Sustained Release Tablet in Patients with Depression:A Randomized,double-Blind,multi-center Clinical Trial

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

Study of Bupropion Hydrochloride Tablet and Fluoxetine in Treatment of Depression Multicenter Clinical Trial

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

Bupropion SR in the treatment of depression comorbid with anxiety:a randomized,double-blind clinical trial

Efficacy and Safety of Bupropion Hydrochloride Extended-Release Versus Escitalopram Oxalate in Chinese Patients with Major Depressive Disorder: Results from a Randomized, Double-Blind, Non-Inferiority Trial.

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

Efficacy and safety of enteric-coted sustained release tablets in the treatment of major depression

Duloxetine Versus Paroxetine in the Treatment of Major Depressive Disorder: a Randomized Double-Blind Multicentre Controlled Study

Comparison of Reboxetine with Fluoxetine in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Effects of Bupropion Sustained-Release on Sexual Functioning and Nocturnal Erections in Healthy Men

Multi-center,randomized,and double-blind controlled clinical trial of duloxetine enteric capsule in treatment of depression

Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation

Treatment of Major Depressive Disorders with Generic Duloxetine and Paroxetine: a Multi-Centered, Double-Blind, Double-Dummy, Randomized Controlled Clinical Trial.

Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials

Venlafaxine in treating 62 patients with depression: a multicenter open trial

Citalopram in the Treatment of Depressive Disorders: an Open Label, Multicenter Study in China

Multidimensional assessment of adverse events of bupropion: A large-scale data analysis from the FAERS database